Assessing AptarGroup (ATR) Valuation After Recent Share Price Weakness

Why AptarGroup is on investors’ radar today

AptarGroup (ATR) has attracted attention after recent share price moves, with a month return of about a 13% decline contrasting with a modest gain over the past 3 months.

For investors tracking packaging and dispensing solution providers, AptarGroup’s current share price of $124.69 and market cap of about $8.1 billion provide a concrete snapshot of how the market is currently valuing its business.

See our latest analysis for AptarGroup.

The recent 13.5% 1 month share price decline comes after a modest 1.8% year to date share price gain and a 15.4% 1 year total shareholder return loss, suggesting momentum has cooled even as the 3 year total shareholder return of 11.7% remains positive.

If you are weighing AptarGroup against other opportunities in industrial and materials related themes, this could be a good moment to scan 20 top founder-led companies

With AptarGroup trading at $124.69 alongside an indicated intrinsic discount of about 28%, the key question for you is simple: is this weakness offering a buying window, or is the market already pricing in future growth?

Most Popular Narrative: 22.8% Undervalued

According to the most followed AptarGroup narrative, a fair value of $161.43 versus the last close at $124.69 points to meaningful upside in the current pricing.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Read the complete narrative.

If you want to see what is backing that $161.43 figure, look at how the narrative blends steady revenue growth, slightly lower margins, and a richer future earnings multiple to reach its conclusion.

Result: Fair Value of $161.43 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, elevated legal costs and uncertain demand for emergency medicine delivery systems could pressure margins and challenge the optimistic earnings and valuation narrative.

Find out about the key risks to this AptarGroup narrative.

Another way to look at AptarGroup’s valuation

The narrative points to a 22.8% discount to fair value, yet AptarGroup trades on a P/E of 20.4x compared with a fair ratio of 18.6x, the global packaging industry at 15.5x and peers at 16.8x. That richer multiple suggests less margin for error if growth or margins disappoint.

Before leaning on the current share price, it is worth stress testing how much P/E compression you would be comfortable with if sentiment shifts, and whether that potential downside still fits your risk profile. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment on AptarGroup is mixed. If this has your attention, review the full data and move quickly to form your own view with 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If AptarGroup has sparked your interest, do not stop here. Broaden your watchlist with focused ideas so you are not caught missing the next opportunity.

• Target steadier performers by reviewing companies that pass a low risk filter using the 69 resilient stocks with low risk scores.
• Hunt for potential mispricing by checking out the 61 high quality undervalued stocks that combine strong fundamentals with attractive valuations.
• Spot future standouts early by scanning the screener containing 25 high quality undiscovered gems before they draw wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com